Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy

References

• Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005; 24:7475-81; PMID: 16288294; http://dx.doi.org/10.1038/sj.onc.1209090
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84; PMID:16469695; http://dx.doi.org/10.1016/j.cell.2006.01.016
   PubMed Web of Science ®Google Scholar
• Rosner M, Hanneder M, Siegel N, Valli A, Hengstschlager M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008; 658:234-46; PMID:18291711; http://dx.doi.org/10.1016/j.mrrev.2008.01.001
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59:490-8; PMID:16453317; http://dx.doi.org/10.1002/ana.20784
   PubMed Web of Science ®Google Scholar
• Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J kidney Dis 2006; 48:e27-9; PMID:16931204; http://dx.doi.org/10.1053/j.ajkd.2006.05.018
   PubMed Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-51; PMID:18184959; http://dx.doi.org/10.1056/NEJMoa063564
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364:1595-606; PMID:21410393; http://dx.doi.org/10.1056/NEJMoa1100391
   PubMed Web of Science ®Google Scholar
• Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280-93; PMID:20965422; http://dx.doi.org/10.1016/j.molcel.2010.09.023
   PubMed Web of Science ®Google Scholar
• Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012; 32:2-11; PMID:22025673; http://dx.doi.org/10.1128/MCB.06159-11
   PubMed Web of Science ®Google Scholar
• White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15:5308-16; PMID:19706824; http://dx.doi.org/10.1158/1078-0432.CCR-07-5023
   PubMed Web of Science ®Google Scholar
• Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M, Wu JJ, Finkel T, Kwiatkowski DJ, Yu JJ, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci U S A 2011; 108:12455-60; PMID:21746920; http://dx.doi.org/10.1073/pnas.1104361108
   PubMed Web of Science ®Google Scholar
• Astrinidis A, Senapedis W, Henske EP. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Hum Mol Genet 2006; 15:287-97; PMID: 16339216; http://dx.doi.org/10.1093/hmg/ddi444
   PubMed Web of Science ®Google Scholar
• de Carcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 2011; 10:2255-62; PMID:21654194; http://dx.doi.org/10.4161/cc.10.14.16494
   PubMed Web of Science ®Google Scholar
• Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60:240-5; PMID: 15176053; http://dx.doi.org/10.1002/pros.20050
   PubMed Web of Science ®Google Scholar
• Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M, Denkert C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446:442-50; PMID:15785925; http://dx.doi.org/10.1007/s00428-005-1212-8
   PubMed Web of Science ®Google Scholar
• Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, Bahra M, Denkert C, Dietel M, Kristiansen G. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005; 5:259-65; PMID:15855824; http://dx.doi.org/10.1159/000085280
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94:148-52; PMID:12708489; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01411.x
   PubMed Web of Science ®Google Scholar
• Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 2007; 67:11106-10; PMID:18056432; http://dx.doi.org/10.1158/0008-5472.CAN-07-2348
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, Nathan RB, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7:275-86; PMID:15766665; http://dx.doi.org/10.1016/j.ccr.2005.02.009
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005; 19:611-3; PMID:15661849
   PubMed Web of Science ®Google Scholar
• Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26:2093-108; PMID:16507989; http://dx.doi.org/10.1128/MCB.26.6.2093-2108.2006
   PubMed Web of Science ®Google Scholar
• Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007; 6:450-9; PMID:17267659; http://dx.doi.org/10.1158/1535-7163.MCT-06-0543
   PubMed Web of Science ®Google Scholar
• Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-22; PMID:17291758; http://dx.doi.org/10.1016/j.cub.2006.12.037
   PubMed Web of Science ®Google Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41; PMID:21102634; http://dx.doi.org/10.1038/nrc2964
   PubMed Web of Science ®Google Scholar
• Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14:1650-6; PMID:15380067; http://dx.doi.org/10.1016/j.cub.2004.08.026
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29:5657-70; PMID:19720745; http://dx.doi.org/10.1128/MCB.00735-09
   PubMed Web of Science ®Google Scholar
• Catania MG, Mischel PS, Vinters HV. Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. J Neuropathol Exp Neurol 2001; 60:711-23; PMID:11444800
   PubMed Web of Science ®Google Scholar
• Astrinidis A, Senapedis W, Coleman TR, Henske EP. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J Biol Chem 2003; 278:51372-9; PMID:14551205; http://dx.doi.org/10.1074/jbc.M303956200
   PubMed Web of Science ®Google Scholar
• Rosner M, Hanneder M, Siegel N, Valli A, Hengstschlager M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008; 658:234-46; PMID:18291711; http://dx.doi.org/10.1016/j.mrrev.2008.01.001
   PubMed Web of Science ®Google Scholar
• Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009; 8:4168-75; PMID:20054236; http://dx.doi.org/10.4161/cc.8.24.10800
   PubMed Web of Science ®Google Scholar
• Gomez-Baldo L, Schmidt S, Maxwell CA, Bonifaci N, Gabaldon T, Vidalain PO, Senapedis W, Kletke A, Rosing M, Barnekow A, et al. TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle 2010; 9:1143; PMID:20237422; http://dx.doi.org/10.4161/cc.9.6.11018
   PubMed Web of Science ®Google Scholar
• Weiss L, Efferth T. Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol 2012; 1:38; PMID:23227884; http://dx.doi.org/10.1186/2162-3619-1-38
   PubMedGoogle Scholar
• Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 2011; 31:2484-98; PMID:21482669; http://dx.doi.org/10.1128/MCB.01061-10
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, et al. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 2012; 4:154ra34; PMID:23035046; http://dx.doi.org/10.1126/scitranslmed.3003840
   PubMed Web of Science ®Google Scholar
• Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008; 29:541-51; PMID:18342602; http://dx.doi.org/10.1016/j.molcel.2007.12.023
   PubMed Web of Science ®Google Scholar
• Kang YJ, Lu MK, Guan KL. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ 2011; 18:133-44; PMID:20616807; http://dx.doi.org/10.1038/cdd.2010.82
   PubMed Web of Science ®Google Scholar
• Verfaillie T, Salazar M, Velasco G, Agostinis P. Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010; 2010:930509; PMID: 20145727; http://dx.doi.org/10.1155/2010/930509
   PubMedGoogle Scholar
• Suzuki T, Das SK, Inoue H, Kazami M, Hino O, Kobayashi T, Yeung RS, Kobayashi K, Tadokoro T, Yamamoto Y. Tuberous sclerosis complex 2 loss-of-function mutation regulates reactive oxygen species production through Rac1 activation. Biochem Biophys Res Commun 2008; 368:132-7; PMID:18230340; http://dx.doi.org/10.1016/j.bbrc.2008.01.077
   PubMed Web of Science ®Google Scholar
• Webber JL, Tooze SA. New insights into the function of Atg9. FEBS Letters 2010; 584:1319-26; PMID:20083107; http://dx.doi.org/10.1016/j.febslet.2010.01.020
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Fujita N, Kanno E, Omori H, Yoshimori T, Itoh T, Fukuda M. Atg16L2, a novel isoform of mammalian Atg16L that is not essential for canonical autophagy despite forming an Atg12-5-16L2 complex. Autophagy 2011; 7:1500-13; PMID:22082872; http://dx.doi.org/10.4161/auto.7.12.18025
   PubMed Web of Science ®Google Scholar
• Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137:1001-4; PMID:19524504; http://dx.doi.org/10.1016/j.cell.2009.05.023
   PubMed Web of Science ®Google Scholar
• Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 2011; 278:403-13; PMID:21182587; http://dx.doi.org/10.1111/j.1742-4658.2010.07965.x
   Web of Science ®Google Scholar
• Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29:1717-9; PMID:20101204; http://dx.doi.org/10.1038/onc.2009.519
   PubMed Web of Science ®Google Scholar
• Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol 2013; 2013:102735; PMID:23840208; http://dx.doi.org/10.1155/2013/102735
   PubMedGoogle Scholar
• Toyoshima M, Ohno K, Katsumoto T, Maki H, Takeshita K. Cellular senescence of angiofibroma stroma cells from patients with tuberous sclerosis. Brain Dev 1999; 21:184-91; PMID:10372905; http://dx.doi.org/10.1016/S0387-7604(99)00008-X
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Blagosklonny MV. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle 2013; 12:3063-9; PMID:23974099; http://dx.doi.org/10.4161/cc.26130
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cho JH, Kim JR. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway. J Gerontol A, Biol Sci Med Sci 2013; 68:1145-56; PMID:23525475; http://dx.doi.org/10.1093/gerona/glt017
   PubMed Web of Science ®Google Scholar
• Petronczki M, Glotzer M, Kraut N, Peters JM. Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev Cell 2007; 12:713-25; PMID:17488623; http://dx.doi.org/10.1016/j.devcel.2007.03.013
   PubMed Web of Science ®Google Scholar
• Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002; 21:8470-6; PMID:12466966; http://dx.doi.org/10.1038/sj.onc.1205962
   PubMed Web of Science ®Google Scholar